{
    "nctId": "NCT00450892",
    "briefTitle": "Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer",
    "officialTitle": "A Phase I-II Study of Lapatinib and Docetaxel as Neoadjuvant Treatment for HER-2 Positive Locally Advanced/Inflammatory or Large Operable Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 129,
    "primaryOutcomeMeasure": "Phase I part: Dose limiting toxicity during cycle 1",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast cancer meeting the following criteria:\n\n  * Phase I\n\n    * Locally advanced or inflammatory disease, or specified subgroup of large operable disease for whom neoadjuvant chemotherapy is appropriate, defined as any 1 of the following:\n\n      * Clinical stage T4a-d, any N (inflammatory breast carcinoma: tumor mass, breast enlargement, oedema and warmth of the skin are often present but not mandatory for the diagnosis)\n      * Any clinical T, N2 or N3 (ipsilateral supraclavicular nodes)\n      * cT3cN0,1 any estrogen receptor (ER)\n      * cT2cN1 any ER\n      * cT2cN0 ER negative\n    * Presence of bilateral breast cancer is allowed\n    * No bone, liver, or other extensive metastases\n\n      * Minimal lung, skin, or nodal metastases may be allowed at the discretion of the investigator (phase I only)\n  * Phase II\n\n    * Locally advanced or inflammatory breast cancer, defined as any 1 of the following:\n\n      * Clinical T4a-d, any N (inflammatory breast carcinoma: tumor mass, breast enlargement, oedema and warmth of the skin are often present but not mandatory for the diagnosis)\n      * Any clinical T, N2 or N3 (ipsilateral supraclavicular nodes)\n      * And M0\n    * Bilateral breast cancer is allowed provided only 1 side is HER2-positive\n    * Any large resectable T2 or T3 breast cancers, M0\n* HER2-positive disease by immunohistochemistry, fluorescent in situ hybridization, and/or chromogenic in situ hybridization\n* No CNS involvement\n* Two frozen trucuts for every core biopsy indicated by the translational research study\n* Hormone receptor status:\n\n  * Estrogen receptor- and/or progesterone receptor-positive or negative tumor\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* WHO performance status 0-2\n* Hemoglobin \\> 10.0 g/dL\n* Absolute neutrophil count \\> 1,500/mm\\^3\n* Platelet count \\> 100,000/mm\\^3\n* Bilirubin \\< 1.5 times upper limit of normal (ULN)\n* AST and ALT \\< 3 times ULN\n* Creatinine \\< 1.5 times ULN\n* No other malignancies within the past 3 years except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix (phase II)\n* LVEF normal by MUGA or ECHO\n* ECG normal\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception 2 weeks prior to, during, and for 1 month after completion of study treatment\n* No current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver disease not requiring therapy as per investigator assessment)\n* No serious cardiac illness or medical condition within the past 6 months including, but not limited to, any of the following:\n\n  * History of documented congestive heart failure\n  * High-risk uncontrolled arrhythmias\n  * Angina pectoris requiring antianginal medication\n  * Clinically significant valvular heart disease\n  * Evidence of transmural infarction on ECG\n  * Poorly controlled hypertension, defined as systolic blood pressure (BP) \\> 180 mm Hg or diastolic BP \\> 100 mm Hg\n* Able to swallow and retain oral medication\n* Accessible for repeat dosing and follow up\n* No concurrent grapefruit juice\n* No active or uncontrolled infection\n* No other serious illness\n* No malabsorption syndrome\n* No other medical condition (i.e., history of chronic alcohol abuse, hepatitis, HIV, and/or cirrhosis)\n* No psychological, familial, sociological, or geographical condition that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior therapy for any cancer, including chemotherapy, radiotherapy, or hormonal therapy for breast cancer (phase I)\n* No prior epidermal growth factor receptor- or HER2-targeted therapy or antibody therapy (phase I)\n* More than 10 days since prior and no concurrent CYP3A4 inducers or inhibitors\n* More than 14 days since prior and no concurrent herbal infusions or dietary supplements\n* No antacids 1 hour before or after lapatinib ditosylate administration\n* No other concurrent investigational therapy or anticancer therapy\n* No concurrent prophylactic antibiotics",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}